X
    學術可視化工作室RC   登錄   提交文稿
學術英文編修

ACTA ONCOLOGICA

期刊標題檢索 ACTA ONCOL 最新評論: All questions must be answered systematically without omission; try to... (2021-12-30)


期刊名稱:   ISSN:   主題領域:   影響因子範圍: -
索引:   類別:   開放訪問:   排序方式:

[ACTA ONCOLOGICA]您好,您是該頁面的第 34739 位訪客。

期刊簡介
期刊名稱ACTA ONCOLOGICA ACTA ONCOLOGICA
LetPub Score
6.5
50 ratings
Rate

Reputation
7.5

Influence
5.2

Speed
8.8

期刊簡稱ACTA ONCOL
ISSN0284-186X
E-ISSN1651-226X
h-index88
CiteScore
CiteScoreSJRSNIPCiteScore Rank
4.300.7830.823
Subject fieldQuartilesRankPercentile
Category: Medicine
Subcategory: Radiology, Nuclear Medicine and Imaging
Q2125 / 333
Category: Medicine
Subcategory: Hematology
Q260 / 137
Category: Medicine
Subcategory: Oncology
Q2191 / 404

自引率 (2023-2024)7.40%自引率趨勢
掲載範囲
Acta Oncologica is a journal for the clinical oncologist and accepts articles within all fields of clinical cancer research. Articles on tumour pathology, experimental oncology, radiobiology, cancer epidemiology and medical radio physics are also welcome, especially if they have a clinical aim or interest. Scientific articles on cancer nursing and psychological or social aspects of cancer are also welcomed. Extensive material may be published as Supplements, for which special conditions apply.
官方網站http://www.tandfonline.com/toc/ionc20/current#.V3t2DtJ9600
在線稿件提交https://mc.manuscriptcentral.com/sonc
開放訪問No
出版商Informa Healthcare
主題領域医学
出版國/地區NORWAY
發行頻率隔月刊行
創刊年1987
每年文章數210每年文章數趨勢
黃金OA百分比34.24%
Web of Science 四分位
2023-2024
WOS Quartile: Q3

CategoryEditionJIF QuartileJIF RankingJIF Percentage
ONCOLOGYSCIEQ3163/322
索引 (SCI or SCIE)Science Citation Index
Science Citation Index Expanded
鏈接到PubMed Central (PMC)https://www.ncbi.nlm.nih.gov/nlmcatalog?term=0284-186X%5BISSN%5D
平均審稿時間 *來自出版商的數據:
來自作者的數據: Average 3 Month(s)
競爭力 *來自作者的數據: About 50%
參考鏈接
相關期刊 【ACTA ONCOLOGICA】CiteScore趨勢
自引率趨勢 每年文章數趨勢
作者評論
*所有的審稿過程指標,如接受率和審稿速度,僅限於用戶提交的稿件。因此,這些指標可能無法準確反映期刊的競爭力或速度。
  • 同一學科的期刊
  • CiteScore趨勢
  • 自引率趨勢
  • 每年文章數趨勢
  •  
    學科內的可信期刊 影響因子
    CA-A CANCER JOURNAL FOR CLINICIANSH-index: 144

    CiteScore: 873.20
    Nature Reviews Clinical OncologyH-index: 127

    CiteScore: 99.40
    NATURE REVIEWS CANCERH-index: 396

    CiteScore: 111.90
    ANNALS OF ONCOLOGYH-index: 210

    CiteScore: 63.90
    CANCER CELLH-index: 295

    CiteScore: 55.20
    JOURNAL OF CLINICAL ONCOLOGYH-index: 494

    CiteScore: 41.20
    LANCET ONCOLOGYH-index: 274

    CiteScore: 62.10
    CANCER RESEARCHH-index: 411

    CiteScore: 16.10
    SEMINARS IN CANCER BIOLOGYH-index: 134

    CiteScore: 26.80
    JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCHH-index: 67

    CiteScore: 18.20
    學科內最受檢索的期刊 頁面查看次數
    CANCER LETTERS326145
    CANCER RESEARCH310919
    BMC CANCER242784
    JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH197875
    INTERNATIONAL JOURNAL OF CANCER188202
    Asian Pacific Journal of Cancer Prevention184134
    CLINICAL CANCER RESEARCH180948
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY171579
    ONCOLOGY REPORTS171159
    CA-A CANCER JOURNAL FOR CLINICIANS163255
  •  

    ACTA ONCOLOGICA ACTA ONCOLOGICA
    明年預測:
    穩步上升 無變化 逐步下降  刷新
  •  

     
  •  

     


首頁    上一頁    1    下一頁    末頁  (頁
/1)
  [ACTA ONCOLOGICA] 的評論撰寫評論
作者: 维尔娜菲茨杰拉德


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2021-12-30 13:16:23 評論於
All questions must be answered systematically without omission; try to fulfill any additional experiments suggested in the comments, provide reasonable explanations if some cannot be conducted; make sure to cite the literature recommended by the reviewer and discuss it thoroughly; double-check the modifications made to the initial draft before submitting the revised manuscript
(0) 讚! | 维尔娜菲茨杰拉德

作者: 维尔娜菲茨杰拉德


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2021-12-30 09:08:02 評論於
After the reviewer completes the scoring of the chapter, they need to write a comprehensive review opinion. This usually includes a brief summary of the article content, evaluation of the article's innovation points, pointing out the shortcomings of the article, and providing suggestions for how the editor should handle the article
(0) 讚! | 维尔娜菲茨杰拉德

作者: 修然小公主


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2021-12-28 23:48:26 評論於
How to respond to reviewer comments?
(0) 讚! | 修然小公主

作者: Oswald Edie


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2021-12-26 23:29:16 評論於
What are the opinions and suggestions of the journal editors? What are the opinions and suggestions of the reviewer? What are the differences between the two?
(0) 讚! | Oswald Edie

作者: Squires


領域: 医学
審稿時間: 3.0 month(s)
結果: 修改後接受


撰寫評論

2018-09-28 14:50:30 評論於
I feel that this journal has not been very good in the past two years, and the quality has gone down.

(0) 讚! | Squires

作者: Jocelyn Albert


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2018-09-28 10:57:33 評論於
Review speed: 3.0 Experience sharing: I feel that this journal is not as good as before in the past two years, and the reviewers are not as serious as before
(0) 讚! | Jocelyn Albert

作者: 凌霄高洁


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2017-07-18 08:57:51 評論於
3-point edge, hoping to maintain stability, a slight increase is also good
(0) 讚! | 凌霄高洁

作者: Gale Onions


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2015-08-23 20:25:04 評論於
Submission success rate: 5.0 Experience sharing: The official magazine of the four Nordic countries, with the majority of authors from these four countries, followed by Europe, a few from the United States, rare from Asia, and none from China in the past two years. The difficulty of submission is very high, with a success rate of about 15% or less. Usually, editors will eliminate a batch of submissions similar to domestic core journals!
(0) 讚! | Gale Onions

作者: 哈罗德耶克斯


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2013-04-12 10:27:07 評論於
Review speed: 3.0 | Submission acceptance rate: 50.0
Experience sharing: In April 2012, I submitted an article to this journal. The first review reply came in one month, saying they were interested and requested revisions (no rejection, I thought the reviewers were kind). So I made the revisions and resubmitted. After two months with no response, I sent a reminder email, and got a quick reply. The reviewers thought the experiments were too simple and requested additional experiments (they were really kind). It took nearly 2 months to complete the additional experiments and resubmit. After one month with no news, I sent another reminder, expressing concern about the lengthy review process and urging for a faster pace. The reply promised faster processing. Less than 2 weeks later, they replied asking for language polishing. After polishing, I resubmitted and received acceptance 3 days later. The whole process took nearly 8 months
(0) 讚! | 哈罗德耶克斯

作者: 凌霄高洁


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2011-06-29 20:34:09 評論於
It looks bullish. If it goes up again tomorrow, it is expected to break through 3 points
(0) 讚! | 凌霄高洁

作者: 凌霄高洁


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2011-04-16 20:36:58 評論於
EF has just been found in 2009
(0) 讚! | 凌霄高洁

作者: 九阴琴心


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2011-04-16 19:49:49 評論於
EF has just been found in 2009
(0) 讚! | 九阴琴心

作者: Eli Josh


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2010-11-08 10:51:58 評論於
My article was rejected after being reviewed for 3 months. It's very straightforward. A bit frustrated, if they were going to reject it, they should have done it sooner instead of dragging it out for so long
(0) 讚! | Eli Josh

作者: 凌霄高洁


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2009-12-15 20:13:27 評論於
Field: Oncology
Country: Sweden
Submission Time: May 2006
Review Time: Initial review 8 weeks, major revision once, return after two months, minor revision, then return after two weeks for acceptance.
Publication Fee: Free
Journal Periodicity: 8 issues per year
Personal Comment: This journal is worth considering for colleagues studying tumors. It leans toward the basic side, and its Impact Factor has risen rapidly in recent years, from a few points to a certain difficulty level. Full-text access is available for free online six months after publication
(0) 讚! | 凌霄高洁

首頁    上一頁    1    下一頁    末頁  (頁
/1)

開始撰寫 [ACTA ONCOLOGICA] 的評論:





Contact us

Contact us  

Your name*

Your email*

Your message*

Please fill in all fields and provide a valid email.

Security Code*